Your browser doesn't support javascript.
loading
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Taylor, Justin; Mi, Xiaoli; Penson, Alexander V; Paffenholz, Stella V; Alvarez, Kelsey; Sigler, Allison; Chung, Stephen S; Rampal, Raajit K; Park, Jae H; Stein, Eytan M; Tallman, Martin S; Sen, Filiz; Gönen, Mithat; Abdel-Wahab, Omar; Klimek, Virginia M.
Afiliación
  • Taylor J; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miam
  • Mi X; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Penson AV; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Paffenholz SV; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Alvarez K; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Sigler A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chung SS; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Rampal RK; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Park JH; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Stein EM; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Tallman MS; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Sen F; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Gönen M; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Abdel-Wahab O; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Klimek VM; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: klimekv@mskcc.org.
Lancet Haematol ; 7(8): e566-e574, 2020 Aug.
Article en En | MEDLINE | ID: mdl-32735836
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Azacitidina / Triazoles / Síndromes Mielodisplásicos / Leucemia Mieloide Aguda / Resistencia a Antineoplásicos / Hidrazinas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Lancet Haematol Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Azacitidina / Triazoles / Síndromes Mielodisplásicos / Leucemia Mieloide Aguda / Resistencia a Antineoplásicos / Hidrazinas Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Lancet Haematol Año: 2020 Tipo del documento: Article